... prognostic and predictive biomarkers which could pave the way toward the development of truly personalized therapy. [email protected] 1 09 2023 17 10 2023 25 10 2023 Breast neoplasms HER2 ERBB2 protein Human Neoadjuvant therapy Trastuzumab HER2...

... neoplasms Neoadjuvant therapy Pathological response The Miller-Payne grading system (MPG) is commonly used to assess pathological response by comparing cancer cellularity in core biopsy samples obtained before treatment with the resected tumor after treatment. pCR entails a >90% reduction...

... receiving neoadjuvant therapy. [email protected] 17 01 2022 12 02 2022 15 2 2022 © 2022 S. Karger AG, Basel 2022 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages...

... survival and shows a trend towards improved overall survival (OS). On the other hand, for low-risk patients, chemotherapy deescalation should be strongly considered with the use of trastuzumab monotherapy as an anti-HER2 backbone. Key Messages: Neoadjuvant therapy should be offered for a significant...

... 1990. Currently, 5-year survival is estimated at 88% and 10-year survival at 82% [ 1 ]. Neoadjuvant therapy (NACT) has been developed as an important therapeutic option. If chemotherapy seems mandatory due to diagnostic and prognostic parameters, it should be scheduled in a neoadjuvant setting [ 2, 3...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Trastuzumab Neoadjuvant therapy Pathologic complete response Adjuvant treatment Survival HER2 is amplified in about 15-25% of breast cancers depending...

...Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández Summary Neoadjuvant therapy (NAT) allows downstaging in some cases of breast cancer. By consequence, it may enable a more conservative surgical approach or make surgery possible in cases ineligible for surgery before NAT...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Intraoperative radiotherapy TARGIT-IORT Neoadjuvant therapy Breast cancer...

... to in the content or advertisements. Breast cancer Mitotic count PHH3 Neoadjuvant therapy We counted PHH3-immunostained mitoses/10 HPF in breast cancer tissues obtained from 72 patients before NACT. The median value for mitoses detected by PHH3/10 HPF was 30.00 mitoses/10 HPF. Of these, 6/72 cases...

... is effective and safe in the neoadjuvant therapy of HER2-positive breast cancer, yielding DFS, DDFS and OS probabilities comparable to the results of adjuvant trials. Our data support the use of TCH as a neoadjuvant therapy regimen for patients with HER2-positive breast cancer. They also strongly encourage...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Neoadjuvant therapy Dose-dense...

... from any ideas, methods, instructions or products referred to in the content or advertisements. 2015 Early breast cancer Bisphosphonates Endocrine therapy Chemotherapy Surgery Axillary dissection Radiotherapy Targeted therapy Neoadjuvant therapy The St. Gallen Consensus...

... Chemotherapy Surgery Axillary dissection Targeted therapy Neoadjuvant therapy © 2013 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means...

...-positive breast cancer, as it raised pCR rates up to 50%. Novel approaches are aiming to increase the efficacy of neoadjuvant therapy. Inclusion of capecitabine might further increase pCR rates in selected patients, although data are not unanimous throughout the respective clinical trials. In patients...

... therapy · Neoadjuvant therapy Schlüsselwörter Frühes Mammakarzinom · Bisphosphonate · Endokrine Therapie · Chemotherapie · Operation · Zielgerichtete Therapie · Neoadjuvante Therapie Summary The 2011 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based treatment...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Early Breast Cancer Endocrine treatment Neoadjuvant therapy Targeted...

... to in the content or advertisements. Breast cancer: early, locally advanced Targeted therapy HER2 Neoadjuvant therapy Trastuzumab Lapatinib Bevacizumab Neratinib T-DM1 Pertuzumab Breast Care Review Article · Übersichtsarbeit Breast Care 2010;5:144 152 DOI: 10.1159/000315047 Published online: June...